Abstract
A 63-year-old female was diagnosed with Lambda light chain myeloma presented as acute kidney injury, requiring dialysis, in the background history of hypertension. She was treated with Cyclophosphamide + Bortezomib + Dexamethasone for 12 cycles. Renal function improved with no ongoing requirement of dialysis. She again presented 2 years later with left femur fracture and bone marrow biopsy confirmed multiple myeloma relapse.
She was started on lenalidomide, dexamethasone and carfilzomib therapy. 2 weeks after this, she presented to the emergency department with shortness of breath and bilateral lung crackles and pitting edema on examination. Chest X ray showed pulmonary congestion. ECG has not changed in comparison with her baseline ECG. Troponin was negative two times. Subsequent echocardiogram showed left ventricular ejection fraction of 32%. She was started on guideline-directed medical therapy (GDMT) of heart failure. CFZ treatment stopped and 3 months later, LVEF improved to 52%.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Takakuwa T, Otomaru I, Araki T, et al. The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case reports in hematology. 2019;(5)2019-24.
Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817–25. https://doi.org/10.1182/blood-2012-05-425934.
Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail. 2015;21(2):138–44.
Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, O'Quinn R, Cohen AD, Stadtmauer EA, Ky B, Weiss BM. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519. Epub 2018 Mar 8. PMID: 29285538; PMCID: PMC5885859. https://doi.org/10.1001/jamaoncol.2017.4519.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1(7):449–54. PMID: 29296960; PMCID: PMC5738981. https://doi.org/10.1182/bloodadvances.2016003269.
Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O’Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37(22):1946–55. Epub 2019 Jun 12. PMID: 31188726. https://doi.org/10.1200/JCO.19.00231.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rohani, A. (2021). Carfilzomib (CFZ) Induced Heart Failure with Reduced Ejection Fraction. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-71155-9_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71154-2
Online ISBN: 978-3-030-71155-9
eBook Packages: MedicineMedicine (R0)